MPO and breast carcinoma: In a multicenter study116 of breast cancer patients undergoing doxorubicin and trastuzumab therapy, the associations of 8 biomarkers including the ultrasensitive troponin I (TnI), high-sensitivity C-reactive protein (CRP), N-terminal pro–B-type natriuretic peptide (NT-proBNP), growth differentiation factor-15, myeloperoxidase (MPO), placental growth factor (PlGF), soluble fms-like tyrosine kinase receptor (sFlt)-1, and galectin (gal)-3 with the successive development of cardiotoxicity were analyzed.